CDXC ChromaDex
- 3.640
- -0.020-0.55%
ChromaDex News
ChromaDex's NIAGEN (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar Cellular Nutrition Cellular Energy Supplement
New ingredient collaboration debuts Solgar's first NAD+ boosting supplement and reinforces NIAGEN as the gold standard in the NAD+ supplement category ChromaDex Corp. (NASDAQ:CDXC), the global authority on
ChromaDex Announces Nationwide Launch of Tru Niagen at The Vitamin Shoppe
Tru Niagen is now available at 700 retail locations of The Vitamin Shoppe and Super Supplements and online at vitaminshoppe.comLOS ANGELES--(BUSINESS WIRE)--$CDXC #CellularHealth--ChromaDex Corp. (NAS
Press Release: ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 LOS ANGELES--(BUSINESS WIRE)--April 24, 2024-- ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen at Sprouts Farmers Market
Tru Niagen expands to health-conscious Sprouts consumers in more than 400 locations across 23 states ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and healthy
ChromaDex Is Maintained at Buy by Roth MKM
ChromaDex Is Maintained at Buy by Roth MKM
Roth MKM: Maintains ChromaDEX (CDXC.US) rating, adjusted from buy to buy rating, and adjusted target price from $4.25 to $6.00.
Roth MKM: Maintains ChromaDEX (CDXC.US) rating, adjusted from buy to buy rating, and adjusted target price from $4.25 to $6.00.
Roth MKM Maintains Buy on ChromaDex, Raises Price Target to $6
Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target from $4.25 to $6.
Should You Investigate ChromaDex Corporation (NASDAQ:CDXC) At US$4.32?
While ChromaDex Corporation (NASDAQ:CDXC) might not have the largest market cap around , it saw a significant share price rise of 218% in the past couple of months on the NASDAQCM. The company's
ChromaDex Announces Tru Niagen Is Now Third-Party Verified Through the Alkemist Assured Transparency Program
All Tru Niagen products (except Tru Niagen 1,000mg, which is NSF Certified for Sport) are Alkemist Assured ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) and
12 Health Care Stocks Moving In Monday's Intraday Session
GainersFresh2 Group (NASDAQ:FRES) shares rose 41.7% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $15.7 million. Akso Health Group (NASDAQ:AHG) stock mov
ChromaDex Corporation's (NASDAQ:CDXC) Shares Leap 47% Yet They're Still Not Telling The Full Story
Despite an already strong run, ChromaDex Corporation (NASDAQ:CDXC) shares have been powering on, with a gain of 47% in the last thirty days.
ChromaDex Is Maintained at Buy by HC Wainwright & Co.
ChromaDex Is Maintained at Buy by HC Wainwright & Co.
HC Wainwright & Co. Maintains Buy on ChromaDex, Raises Price Target to $6
HC Wainwright & Co. analyst Raghuram Selvaraju maintains ChromaDex (NASDAQ:CDXC) with a Buy and raises the price target from $5 to $6.
ChromaDex Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/11/2024 246.82% HC Wainwright & Co. $5 → $6 Maintains Buy 08/10/2023 189.02% HC Wainwright & Co. → $5 R
ChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results With Positive Adjusted EBITDA
Earnings Call Summary | ChromaDex(CDXC.US) Q4 2023 Earnings Conference
The following is a summary of the ChromaDex Corporation (CDXC) Q4 2023 Earnings Call Transcript:Financial Performance:ChromaDex reported Q4 revenue of $21.2 million, a positive adjusted EBITDA of $1.2
ChromaDex Expects Trajectory Of 2024 Revenue Growth To Continue, Projecting Higher Rate Of Revenue Growth Than Prior Year Growth Of 16%
ChromaDex Expects Trajectory Of 2024 Revenue Growth To Continue, Projecting Higher Rate Of Revenue Growth Than Prior Year Growth Of 16%
Chromadex Releases Insightful Corporate Presentation Online
ChromaDex Q4 EPS $0.00 Beats $(0.03) Estimate, Sales $21.20M Beat $20.98M Estimate
ChromaDex (NASDAQ:CDXC) reported quarterly earnings of $0.00 per share which beat the analyst consensus estimate of $(0.03) by 103.33 percent. This is a 105 percent increase over losses of $(0.02) per
Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q4 Revenue $21.2M, Vs. Street Est of $20.7M
04:04 PM EST, 03/06/2024 (MT Newswires) -- Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q4 Revenue $21.2M, vs. Street Est of $20.7M
Analysis
Price Target
No Data
